New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 14, 2014
07:17 EDTNVS, DEO, ITYBY, BTI, SHPG, GSKCredit Suisse to hold a conference
Stockholm Consumer & Healthcare IR Day to be held in Stockholm, Sweden on May 14.
News For BTI;DEO;GSK;ITYBY;NVS;SHPG From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
March 19, 2015
15:13 EDTNVSAmgen denied preliminary injunction for biologics against Novartis, Reuters says
15:12 EDTGSKFDA panel says Breo lacks efficacy data in children with asthma, Bloomberg says
Subscribe for More Information
10:02 EDTDEOOn The Fly: Analyst Initiation Summary
Subscribe for More Information
07:26 EDTGSKFDA to hold a joint advisory committee meeting
The Pulmonary-Allergy Drugs Advisory Committee and the Drug Safety & Risk Management Advisory Committee discuss the supplemental New Drug Application (sNDA) 204275-S001, for fluticasone furoate and vilanterol dry powder for inhalation (with the brand name of BREO® ELLIPTA®), sponsored by Glaxo Group Limited (d/b/a GSK) for the once-daily treatment for asthma in patients aged 12 years and older in a meeting being held in Gaithersburg, Maryland on March 19 at 8 am. Webcast Link
07:10 EDTGSKTheravance announces trading in common stock halted as FDA meets on sNDA
Subscribe for More Information
05:33 EDTDEODiageo initiated with a Neutral at Exane BNP Paribas
Subscribe for More Information
March 18, 2015
08:03 EDTSHPGTherapeuticsMD names Angus Russell, J. Martin Carroll as directors
TherapeuticsMD (TXMD) announced the appointment of two biopharmaceutical senior executives, Angus C. Russell and J. Martin Carroll, as independent members of its board of directors, and that Randall S. Stanicky has stepped down from the board of directors. Angus C. Russell served as CEO of Shire PLC (SHPG) from June 2008 until April 2013. J. Martin Carroll served as president and CEO of Boehringer Ingelheim Corp. U.S. from 2003 until 2011.
07:22 EDTSHPGShire looking for 'transformational' deal, Betaville blog says
Subscribe for More Information
March 17, 2015
12:51 EDTNVSNovartis hit with $100M gender discrimination lawsuit, Reuters reports
A proposed class action lawsuit against Novartis claims the drug maker routinely denied female employees equal pay and promotional opportunities, reports Reuters. The $110M lawsuit filed on Tuesday says Novartis' Alcon Laboratories maintains a "boy's club atmosphere" that is hostile to women and bars them from leadership positions. Reference Link
07:07 EDTGSKVeeva says selected by GlaxoSmithKline for multichannel CRM
Subscribe for More Information
07:06 EDTGSKVeeva selected by GSK as global multichannel CRM partner
Subscribe for More Information
05:32 EDTNVSIncyte announces Novartis receives EC approval for Jakavi
Incyte (INCY) announced that Novartis (NVS) received approval from the European Commission for Jakavi for the treatment of adult patients with polycythemia vera, or PV, who are resistant to or intolerant of hydroxyurea. Jakavi is the first targeted treatment approved by the European Commission for these patients. Under the Incyte-Novartis Collaboration and License Agreement signed in 2009, Novartis received exclusive development and commercialization rights to ruxolitinib outside of the United States for all hematologic and oncologic indications, and sells ruxolitinib under the name Jakavi. Ruxolitinib is marketed by Incyte in the United States as Jakafi. Jakafi is approved by the FDA for treatment of people with polycythemia vera who have had an inadequate response to or are intolerant of hydroxyurea. Jakafi is also indicated for treatment of people with intermediate or high-risk myelofibrosis, or MF, including primary MF, post–polycythemia vera MF, and post–essential thrombocythemia MF.
05:30 EDTNVSNovartis receives EU approval for Jakavi in polycythemia vera
Novartis announced that the European Commission has approved Jakavi for the treatment of adult patients with polycythemia vera, or PV, who are resistant to or intolerant of hydroxyurea. Jakavi is the first targeted treatment approved by the European Commission for these patients. Jakavi is the only JAK 1/2 inhibitor available to treat PV and is also currently approved in more than 80 countries to treat myelofibrosis.
March 16, 2015
13:02 EDTDEODiageo files automatic mixed securities shelf
Subscribe for More Information
07:32 EDTGSKEmergent BioSolutions signs agreements with GSK, Oxford University, NIAID
Subscribe for More Information
07:16 EDTDEOConsumer Analyst Group of Europe to hold a conference
Subscribe for More Information
March 15, 2015
15:59 EDTITYBYFTC increases scrutiny on Reynolds-Lorillard deal, WSJ says
Subscribe for More Information
March 13, 2015
10:00 EDTDEOOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: Aramark (ARMK) downgraded to Neutral from Outperform at RW Baird... Broadcom (BRCM) downgraded to Hold from Buy at Canaccord... Children's Place (PLCE) downgraded to Neutral from Buy at Citigroup... Depomed (DEPO) downgraded to Hold from Buy at WallachBeth... Diageo (DEO) downgraded to Underperform from Neutral at Credit Suisse... DreamWorks (DWA) downgraded to Neutral from Buy at B. Riley... Gaming and Leisure Properties (GLPI) downgraded to Neutral at Susquehanna... Genesco (GCO) downgraded at Sterne Agee... Host Hotels (HST) downgraded to Underperform from Market Perform at Raymond James... InspireMD (NSPR) downgraded at Oppenheimer... Integrated Silicon (ISSI) downgraded to Neutral from Buy at B. Riley... InterXion (INXN) downgraded to Market Perform from Outperform at Raymond James... JG Wentworth (JGW) downgraded to Hold from Buy at Jefferies... Lumber Liquidators (LL) downgraded to Neutral from Buy at Goldman... QIWI (QIWI) downgraded to Neutral at Susquehanna... Regional Management (RM) downgraded to Underperform from Neutral at Macquarie... Royal Dutch Shell (RDS.A) downgraded to Sector Perform from Outperform at RBC Capital... Rudolph Technologies (RTEC) downgraded to Neutral from Buy at DA Davidson.
05:48 EDTDEODiageo downgraded to Underperform from Neutral at Credit Suisse
Subscribe for More Information
05:40 EDTNVSNovartis to present Cosentyx data at AAD 2015
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use